Indianapolis, IN1 Active Studies

Primary Biliary Cholangitis Clinical Trials in Indianapolis, IN

Find 1 actively recruiting primary biliary cholangitis clinical trials in Indianapolis, IN. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
386
Enrolling

Recruiting Primary Biliary Cholangitis Studies in Indianapolis

About Primary Biliary Cholangitis Clinical Trials in Indianapolis

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease in which the bile ducts in the liver are slowly destroyed. This leads to bile buildup, liver damage, and potentially cirrhosis. Treatment includes ursodeoxycholic acid and obeticholic acid.

There are currently 1 primary biliary cholangitis clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 386 participants. Research is being sponsored by Zydus Therapeutics Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Primary Biliary Cholangitis Clinical Trials in Indianapolis — FAQ

Are there primary biliary cholangitis clinical trials in Indianapolis?

Yes, there are 1 primary biliary cholangitis clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What primary biliary cholangitis treatments are being tested?

The 1 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for primary biliary cholangitis.

Data updated October 16, 2026 from ClinicalTrials.gov